SANTA FE, N.M. (AP) — New Mexico brought recreational marijuana sales to the doorstep of Texas, the largest prohibition state, as the movement toward broad legalization sweeps up even more of the American West.
It was the first census after World War II. The baby boom had begun. The Great Migration of Black residents from the Jim Crow South to places like Detroit and Chicago was in full swing. And some industrial cities reached
WASHINGTON (AP) — U.S. airport security procedures will become more gender-neutral, with changes to scanners used for screening and the use of an “X” for travelers going through Precheck who do not identify as male or female, the Biden administration
OTTAWA — The body representing Canada's songwriters and composers has revealed that on average musicians writing their own material earned only $67 last year in royalties from domestic streaming services.
SOCAN, which collects the royalties of musicia...
WASHINGTON (AP) — Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease, a potential setback for patient groups who have lobbied for the medication’s approval.
Proponents of restrictions on how U.S. public schools address sexual orientation and gender identity say their ultimate goal is to allow parents more involvement in their children's education and ensure classroom materials are age-appropriate.
MADRID (AP) — The European Union's drug regulator said Tuesday it has begun an accelerated review process for an experimental coronavirus vaccine booster made by the Spanish company Hipra.
HORDYNIA, Ukraine (AP) — Planting season has arrived in Ukraine. Boot marks stamped in the frozen earth have thawed. But the Pavlovych family's fields remain untouched in a lonely landscape of checkpoints and churches.
TALLAHASSEE, Fla. (AP) — Florida has come under intense national scrutiny over legislation that critics have labeled the “Don't Say Gay" law.
The GOP legislation, which Republican
WASHINGTON (AP) — Federal health regulators issued a negative review Monday of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, after months of lobbying by patient advocates urging approval.